PTK2 and thyroid cancer: FAK is overexpressed and phosphorylated in a multitude of cancers including thyroid cancer and represents a promising therapeutic target to halt FAK mediated tumorigenic processes including growth, drug resistance, invasion, cell survival, and metastasis (3–13, 48–51).